ectoin
Commercial- Indications
- Allergy, Dermatitis, Respiratory diseases, Eye irritation
Company intelligence / Profile preview
bitop AG
Dortmund, Nordrhein-Westfalen, Germanybitop.de ↗
- Ownership
- Private
- Employees
- ~42
- Development stage
- Commercial
01
Overview
Bitop has developed commercial products based on Ectoin® and other extremolytes. Clinical trials have shown Ectoin reduces symptoms of acute allergic rhinitis and may positively influence lung inflammation.
- Therapeutic areas
- OtherImmunologyDermatologyPulmonology
- Modalities
- ExtremolytesNatural compounds
- Industry
- Therapeutic Medical Devices
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Merck KGaA (Darmstadt)Banxa
Beyond the preview
Go deeper on bitop AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bitop AG.